Trials / Unknown
UnknownNCT06079827
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 43 (estimated)
- Sponsor
- MaxWell Clinic, PLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.
Detailed description
Participants with a diagnosis of Alzheimer's or Mild Cognitive Impairment will undergo therapeutic plasma exchange as part of their treatment for the disease as per the AMBAR Trial protocol. Patients will undergo one non-invasive tests to assess their microvascular system and complete one online test to assess the degree of cognitive impairment. Patients will have their blood drawn pre-plasma exchange, immediately post plasma exchange and repeated assessments and blood draws at seven day intervals post plasma exchange ending on the twenty-eighth day after the plasma exchange. Their blood will be analyzed by FBB Biomed to identify the presence of unique RNA biomarkers associated with Alzheimer's disease and determine how quickly they regenerate.
Conditions
Timeline
- Start date
- 2022-03-22
- Primary completion
- 2024-09-01
- Completion
- 2025-09-01
- First posted
- 2023-10-12
- Last updated
- 2023-10-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06079827. Inclusion in this directory is not an endorsement.